CN103458930B - 针对cd74的人抗体和抗体-药物缀合物 - Google Patents

针对cd74的人抗体和抗体-药物缀合物 Download PDF

Info

Publication number
CN103458930B
CN103458930B CN201280015984.XA CN201280015984A CN103458930B CN 103458930 B CN103458930 B CN 103458930B CN 201280015984 A CN201280015984 A CN 201280015984A CN 103458930 B CN103458930 B CN 103458930B
Authority
CN
China
Prior art keywords
antibody
cancer
antibodies
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280015984.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103458930A (zh
Inventor
S.弗普洛根
M.奥弗迪克
R.V.迪杰库伊曾
W.K.布里克
P.v.伯克尔
P.帕伦
S.里斯比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jian Mabao
Genmab AS
Original Assignee
Jian Mabao
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jian Mabao, Genmab AS filed Critical Jian Mabao
Publication of CN103458930A publication Critical patent/CN103458930A/zh
Application granted granted Critical
Publication of CN103458930B publication Critical patent/CN103458930B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280015984.XA 2011-02-01 2012-02-01 针对cd74的人抗体和抗体-药物缀合物 Active CN103458930B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161438383P 2011-02-01 2011-02-01
DKPA201100064 2011-02-01
US61/438,383 2011-02-01
DKPA201100064 2011-02-01
PCT/EP2012/051679 WO2012104344A1 (en) 2011-02-01 2012-02-01 Human antibodies and antibody-drug conjugates against cd74

Publications (2)

Publication Number Publication Date
CN103458930A CN103458930A (zh) 2013-12-18
CN103458930B true CN103458930B (zh) 2019-10-15

Family

ID=45560912

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280015984.XA Active CN103458930B (zh) 2011-02-01 2012-02-01 针对cd74的人抗体和抗体-药物缀合物

Country Status (12)

Country Link
US (3) US9540433B2 (enExample)
EP (1) EP2670440B1 (enExample)
JP (1) JP6261341B2 (enExample)
CN (1) CN103458930B (enExample)
AU (1) AU2012213437B2 (enExample)
CA (1) CA2826186C (enExample)
ES (1) ES2700514T3 (enExample)
IL (1) IL227477B (enExample)
MX (1) MX350200B (enExample)
RU (1) RU2636029C2 (enExample)
SG (2) SG10201608138RA (enExample)
WO (1) WO2012104344A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578397B1 (en) 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
WO2004110260A2 (en) 2003-06-10 2004-12-23 Neomedix Corporation Device and methods useable for treatment of glaucoma and other surgical procedures
CN104497143B (zh) * 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
US9872799B2 (en) 2012-04-24 2018-01-23 The Regents Of The University Of Colorado, A Body Corporate Intraocular device for dual incisions
US10682254B2 (en) 2012-04-24 2020-06-16 The Regents Of The University Of Colorado, A Body Corporate Intraocular device for dual incisions
EP2841034B1 (en) 2012-04-24 2020-07-29 The Regents of The University of Colorado, A Body Corporate Modified dual-blade cutting system
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014037419A1 (en) * 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US10450354B2 (en) 2013-03-12 2019-10-22 Molecular Templates, Inc. CD20-binding immunotoxins for inducing cellular internalization and methods using same
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
EP2989202B1 (en) 2013-04-25 2019-04-10 Sutro Biopharma, Inc. The use of lambda-gam protein in ribosomal display technology
EP3015116B1 (en) * 2013-06-24 2020-02-26 ABLBio Antibody-drug conjugate having improved stability and use thereof
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015067277A1 (en) 2013-11-07 2015-05-14 University Of Copenhagen Timp-1 binding partner
EP3092255A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors
IL285403B2 (en) 2014-01-27 2023-10-01 Molecular Templates Inc Polypeptides that remove an epitope for MHC group I
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
EP3708227A1 (en) * 2014-07-22 2020-09-16 Sutro Biopharma, Inc. Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
JP6826527B2 (ja) * 2014-09-18 2021-02-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カテプシンｓ阻害をモニタリングするための方法
CN104280553B (zh) * 2014-09-22 2016-06-08 中国人民解放军第二军医大学 一种小鼠源性可溶型cd74蛋白的elisa检测试剂盒及检测方法
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107530376A (zh) 2015-02-18 2018-01-02 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
IL287500B2 (en) 2015-04-21 2023-12-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EP3359194A4 (en) 2015-10-06 2019-04-24 Merck Sharp & Dohme Corp. ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
US10779991B2 (en) 2015-12-23 2020-09-22 The Regents of the University of Colorado, a body corporated Ophthalmic knife and methods of use
BR112018012876A2 (en) 2015-12-23 2018-12-04 The Regents Of The University Of Colorado, A Body Corporate ophthalmic scalpel and methods of use
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
MX2018009085A (es) * 2016-01-27 2019-05-09 Sutro Biopharma Inc Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
CA3010623A1 (en) * 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US9709386B1 (en) * 2016-04-05 2017-07-18 Kla-Tencor Corporation Apparatus and methods for measuring properties in a TSV structure using beam profile reflectometry
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JP7075125B2 (ja) * 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
AU2017278573A1 (en) * 2016-06-06 2019-01-03 Linxis B.V. Cell targeting conjugates
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
JP7075134B2 (ja) 2016-12-07 2022-05-25 モレキュラー テンプレーツ，インク． 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
JP2020507409A (ja) 2017-02-16 2020-03-12 ネオメディックス コーポレイションＮｅｏｍｅｄｉｘ Ｃｏｒｐｏｒａｔｉｏｎ 侵襲性を最小限とした緑内障手術のためのデバイス、システム及び方法
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200019226A (ko) 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물
EP3658588A1 (en) * 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof
BR112020007302B1 (pt) * 2017-10-14 2023-01-31 Abbvie Inc. Anticorpos ativáveis conjugados anti-cd71, método para fabrica-los, composição farmacêutica e kit que compreende os mesmos, usos dos ditos anticorpos, bem como método in vitro para detectar a presença ou ausência do agente de clivagem na amostra
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
JP2024543822A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
WO2023177761A2 (en) 2022-03-16 2023-09-21 Sight Sciences, Inc. Devices and methods for intraocular tissue manipulation
EP4525939A2 (en) * 2022-05-20 2025-03-26 The Regents Of The University Of California Radioimmunoconjugates and therapeutic uses thereof
CA3266080A1 (en) * 2022-09-07 2024-03-14 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. ANTI-TROP2/EGFR ANTIBODIES AND THEIR USES
CN120380021A (zh) * 2022-12-19 2025-07-25 百奥赛图(北京)医药科技股份有限公司 抗pdl1抗体及其用途
CN116139267A (zh) * 2023-01-28 2023-05-23 华中科技大学同济医学院附属同济医院 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用
CN116549499B (zh) * 2023-06-07 2025-01-07 广东省九转生物医药有限公司 商陆果发酵液提取物有效部位在制备抗肿瘤药物中的用途
AU2024302737A1 (en) * 2023-06-16 2026-01-08 Ohio State Innovation Foundation Cd74 car-t therapy and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN117866909B (zh) * 2024-01-29 2024-09-03 华中科技大学同济医学院附属同济医院 一种杂交瘤细胞株及其在生产cd74单克隆抗体上的应用
FR3163370A1 (fr) * 2024-06-18 2025-12-19 Hospices Civils De Lyon Compose inhibiteur de la proteine cd74 et ses utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649902A (zh) * 2002-03-01 2005-08-03 免疫医疗公司 内在化抗－cd74抗体和使用方法
WO2007112193A2 (en) * 2006-03-23 2007-10-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
JP4959136B2 (ja) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649902A (zh) * 2002-03-01 2005-08-03 免疫医疗公司 内在化抗－cd74抗体和使用方法
WO2007112193A2 (en) * 2006-03-23 2007-10-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a HumanMultipleMyeloma Xenograft and in Monkeys;Puja Sapra, et al.;《Clinical Cancer Research》;20050715;第11卷(第14期);5257-5264 *
Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin;Chien-Hsing Chang, et al.;《blood》;20050818;第106卷(第13期);4308-4314 *
Puja Sapra, et al..Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a HumanMultipleMyeloma Xenograft and in Monkeys.《Clinical Cancer Research》.2005,第11卷(第14期),5257-5264. *

Also Published As

Publication number Publication date
IL227477B (en) 2021-08-31
EP2670440A1 (en) 2013-12-11
RU2013140433A (ru) 2015-03-10
JP6261341B2 (ja) 2018-01-17
MX350200B (es) 2017-08-30
US20170173151A1 (en) 2017-06-22
CA2826186A1 (en) 2012-08-09
US9540433B2 (en) 2017-01-10
IL227477A0 (en) 2013-09-30
SG191977A1 (en) 2013-08-30
MX2013008832A (es) 2013-09-06
RU2636029C2 (ru) 2017-11-17
EP2670440B1 (en) 2018-09-05
AU2012213437B2 (en) 2016-08-18
ES2700514T3 (es) 2019-02-18
SG10201608138RA (en) 2016-11-29
JP2014507138A (ja) 2014-03-27
CN103458930A (zh) 2013-12-18
US20140030273A1 (en) 2014-01-30
WO2012104344A1 (en) 2012-08-09
AU2012213437A1 (en) 2013-05-02
CA2826186C (en) 2020-08-04
US20220323582A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US20220323582A1 (en) Human antibodies and antibody-drug conjugates against cd74
US20210395384A1 (en) Human antibody drug conjugates against tissue factor
EP2234641B1 (en) Monoclonal antibodies against cd32b
BRPI0607486B1 (pt) Anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
NZ717560A (en) Human antibodies and antibody-drug conjugates against cd74
HK1191881B (en) Human antibodies and antibody-drug conjugates against cd74
HK1191881A (en) Human antibodies and antibody-drug conjugates against cd74
BR112013019564B1 (pt) Anticorpos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, e, uso de um anticorpo
NZ717560B2 (en) Human antibodies and antibody-drug conjugates against cd74
AU2013203136A1 (en) Human antibody drug conjugates against tissue factor
EP4688863A1 (en) Methods of use of multi-specific binding proteins
EA046448B1 (ru) Способ получения конъюгата антитела человека против тканевого фактора с ауристатином
HK1184469A (en) Human antibody drug conjugates against tissue factor
HK1184469B (en) Human antibody drug conjugates against tissue factor
NZ734153A (en) Human antibodies against tissue factor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Copenhagen

Applicant after: Jian Mabao

Address before: Copenhagen

Applicant before: Genmab AS

GR01 Patent grant
GR01 Patent grant